fashion -WSS

fashion

author：leisure time 2025-10-01 20:12:40 - browse：14822

Illustration of a prescription bottle image on the screen of a smart phone – medical tech coverage from STAT — Alex Hogan/STAT

In another sign of the business headwinds facing prescription mental health apps, developer Twill will shop around for a pharmaceutical company to market Aspiro, its cognitive behavioral therapy treatment for both generalized anxiety and major depression.

Twill executives told STAT the company hopes that a drugmaker developing or currently marketing a product for generalized anxiety, or GAD, and major depressive disorder, or MDD, will be interested in adding a digital therapeutic to boost the effect of its drug — as well as its sales. Twill’s chief strategy officer Chris Wasden said that after watching companies built around prescription digital therapeutics, or PDTs, stall out, Twill made the decision earlier this year that it would only take the product to market if it found a willing drugmaker to serve as its partner.

“A PDT is going to be more valuable in the hands of a drug company that has a drug that they would like to get greater adherence [and] greater revenues from rather than trying to get reimbursement for the PDT itself,” he said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Apellis safety probe of eye disease drug centers on injection needle

knowledge

WSS

Adam's Biotech Scorecard: Do Sarepta's exon

Appeals court upholds limits to abortion pill

What will save rural psychiatry services? Higher Medicaid payments

FDA panel gives mixed vote on blood pressure devices

Insmed lung disease drug hits target in key Phase 3 trial

How to make Best Hospitals ratings actually useful for patients

hotspot

fashion

knowledge

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

How a symptom of dementia informs our understanding of creativity

Alkermes shareholders re

Feds fine Medicare Advantage plans for overcharging members

Medicare details structure of new drug price negotiation program

Antibiotic resistance nearly killed me, so I'm raising awareness of it

BioMarin wins approval for gene therapy to treat hemophilia A

iTeos Therapeutics debuts first data on TIGIT

Cancer drug shortages should be causing more outrage

Prosthetic arm enables patients to feel the objects they grip

knowledge

Adam's Biotech Scorecard: Do Sarepta's exon

Dark money group runs ads on China biotech bill

What will save rural psychiatry services? Higher Medicaid payments

NYU Langone launches private ChatGPT for its health care data

AI used to predict Covid

Diversity in medical illustrations gets boost from Chidiebere Ibe

knowledge

focus

knowledge

hotspot